Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 115

1.

Inflammation and bone erosion are suppressed in models of rheumatoid arthritis following treatment with a novel Syk inhibitor.

Pine PR, Chang B, Schoettler N, Banquerigo ML, Wang S, Lau A, Zhao F, Grossbard EB, Payan DG, Brahn E.

Clin Immunol. 2007 Sep;124(3):244-57. Epub 2007 May 29.

PMID:
17537677
2.

R406, an orally available spleen tyrosine kinase inhibitor blocks fc receptor signaling and reduces immune complex-mediated inflammation.

Braselmann S, Taylor V, Zhao H, Wang S, Sylvain C, Baluom M, Qu K, Herlaar E, Lau A, Young C, Wong BR, Lovell S, Sun T, Park G, Argade A, Jurcevic S, Pine P, Singh R, Grossbard EB, Payan DG, Masuda ES.

J Pharmacol Exp Ther. 2006 Dec;319(3):998-1008. Epub 2006 Aug 31. Erratum in: J Pharmacol Exp Ther. 2013 May;345(2):326.

3.

Role of spleen tyrosine kinase inhibitors in the management of rheumatoid arthritis.

Scott DL.

Drugs. 2011 Jun 18;71(9):1121-32. doi: 10.2165/11591480-000000000-00000. Review.

PMID:
21711059
4.

Treatment of rheumatoid arthritis with a Syk kinase inhibitor: a twelve-week, randomized, placebo-controlled trial.

Weinblatt ME, Kavanaugh A, Burgos-Vargas R, Dikranian AH, Medrano-Ramirez G, Morales-Torres JL, Murphy FT, Musser TK, Straniero N, Vicente-Gonzales AV, Grossbard E.

Arthritis Rheum. 2008 Nov;58(11):3309-18. doi: 10.1002/art.23992.

5.

Immunotoxicity assessment for the novel Spleen tyrosine kinase inhibitor R406.

Zhu Y, Herlaar E, Masuda ES, Burleson GR, Nelson AJ, Grossbard EB, Clemens GR.

Toxicol Appl Pharmacol. 2007 Jun 15;221(3):268-77. Epub 2007 Mar 31.

PMID:
17490694
6.

A novel spleen tyrosine kinase inhibitor blocks c-Jun N-terminal kinase-mediated gene expression in synoviocytes.

Cha HS, Boyle DL, Inoue T, Schoot R, Tak PP, Pine P, Firestein GS.

J Pharmacol Exp Ther. 2006 May;317(2):571-8. Epub 2006 Feb 1.

7.

The active metabolite of spleen tyrosine kinase inhibitor fostamatinib abrogates the CD4⁺ T cell-priming capacity of dendritic cells.

Platt AM, Benson RA, McQueenie R, Butcher JP, Braddock M, Brewer JM, McInnes IB, Garside P.

Rheumatology (Oxford). 2015 Jan;54(1):169-77. doi: 10.1093/rheumatology/keu273. Epub 2014 Jul 26.

PMID:
25065010
8.

Selective spleen tyrosine kinase inhibition delays autoimmune arthritis in mice.

Zhang Z, Cao C, Sun S, Xu Q.

Mol Med Rep. 2015 Aug;12(2):2902-6. doi: 10.3892/mmr.2015.3759. Epub 2015 May 8.

PMID:
25955571
9.

The novel Syk inhibitor R406 reveals mechanistic differences in the initiation of GPVI and CLEC-2 signaling in platelets.

Spalton JC, Mori J, Pollitt AY, Hughes CE, Eble JA, Watson SP.

J Thromb Haemost. 2009 Jul;7(7):1192-9. doi: 10.1111/j.1538-7836.2009.03451.x. Epub 2009 Apr 24.

10.

B-cell antigen receptor signaling enhances chronic lymphocytic leukemia cell migration and survival: specific targeting with a novel spleen tyrosine kinase inhibitor, R406.

Quiroga MP, Balakrishnan K, Kurtova AV, Sivina M, Keating MJ, Wierda WG, Gandhi V, Burger JA.

Blood. 2009 Jul 30;114(5):1029-37. doi: 10.1182/blood-2009-03-212837. Epub 2009 Jun 2.

11.

The Syk-kinase inhibitor R406 impairs platelet activation and monocyte tissue factor expression triggered by heparin-PF4 complex directed antibodies.

Lhermusier T, van Rottem J, Garcia C, Xuereb JM, Ragab A, Martin V, Gratacap MP, Sié P, Payrastre B.

J Thromb Haemost. 2011 Oct;9(10):2067-76. doi: 10.1111/j.1538-7836.2011.04470.x.

12.

Specific inhibition of spleen tyrosine kinase suppresses leukocyte immune function and inflammation in animal models of rheumatoid arthritis.

Coffey G, DeGuzman F, Inagaki M, Pak Y, Delaney SM, Ives D, Betz A, Jia ZJ, Pandey A, Baker D, Hollenbach SJ, Phillips DR, Sinha U.

J Pharmacol Exp Ther. 2012 Feb;340(2):350-9. doi: 10.1124/jpet.111.188441. Epub 2011 Oct 31.

13.

The status of fostamatinib in the treatment of rheumatoid arthritis.

Morales-Torres J.

Expert Rev Clin Immunol. 2012 Sep;8(7):609-15. doi: 10.1586/eci.12.63.

PMID:
23078058
14.
15.

Spleen tyrosine kinase (Syk) inhibitor fostamatinib limits tissue damage and fibrosis in a bleomycin-induced scleroderma mouse model.

Pamuk ON, Can G, Ayvaz S, Karaca T, Pamuk GE, Demirtas S, Tsokos GC.

Clin Exp Rheumatol. 2015 Jul-Aug;33(4 Suppl 91):S15-22. Epub 2015 Jul 6.

PMID:
26148346
16.

A Novel Triazolopyridine-Based Spleen Tyrosine Kinase Inhibitor That Arrests Joint Inflammation.

Ferguson GD, Delgado M, Plantevin-Krenitsky V, Jensen-Pergakes K, Bates RJ, Torres S, Celeridad M, Brown H, Burnett K, Nadolny L, Tehrani L, Packard G, Pagarigan B, Haelewyn J, Nguyen T, Xu L, Tang Y, Hickman M, Baculi F, Pierce S, Miyazawa K, Jackson P, Chamberlain P, LeBrun L, Xie W, Bennett B, Blease K.

PLoS One. 2016 Jan 12;11(1):e0145705. doi: 10.1371/journal.pone.0145705. eCollection 2016.

17.

A spleen tyrosine kinase inhibitor reduces the severity of established glomerulonephritis.

Smith J, McDaid JP, Bhangal G, Chawanasuntorapoj R, Masuda ES, Cook HT, Pusey CD, Tam FW.

J Am Soc Nephrol. 2010 Feb;21(2):231-6. doi: 10.1681/ASN.2009030263. Epub 2009 Dec 3.

18.

Blockade of Syk ameliorates the development of murine sclerodermatous chronic graft-versus-host disease.

Le Huu D, Kimura H, Date M, Hamaguchi Y, Hasegawa M, Hau KT, Fujimoto M, Takehara K, Matsushita T.

J Dermatol Sci. 2014 Jun;74(3):214-21. doi: 10.1016/j.jdermsci.2014.02.008. Epub 2014 Mar 12.

PMID:
24679982
19.
20.

An oral Syk kinase inhibitor in the treatment of rheumatoid arthritis: a three-month randomized, placebo-controlled, phase II study in patients with active rheumatoid arthritis that did not respond to biologic agents.

Genovese MC, Kavanaugh A, Weinblatt ME, Peterfy C, DiCarlo J, White ML, O'Brien M, Grossbard EB, Magilavy DB.

Arthritis Rheum. 2011 Feb;63(2):337-45. doi: 10.1002/art.30114.

Supplemental Content

Support Center